Durability of Urethral Bulking Agent Injection for Female Stress Urinary Incontinence: 2-Year Multicenter Study Results

Gamal Ghoniem, Jacques Corcos, Craig Comiter, O. Lenaine Westney, Sender Herschorn

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Purpose: We evaluated the durability of the urethral bulking agent Macroplastique® for stress urinary incontinence in a 24-month study in women with a previously documented successful outcome 12 months after the last injection. Materials and Methods: In a multicenter study females diagnosed with stress urinary incontinence primarily due to intrinsic sphincter deficiency successfully treated with Macroplastique, defined as 1 or greater Stamey grade improvement 12 months from baseline, were followed for 24 months to assess the sustained therapeutic response. Outcome measures were Stamey grade, Patient Global Impression of Improvement, Physician Assessment of Improvement, 1-hour pad weight, Incontinence Quality of Life scores and safety assessment. Results: At 24 months 56 of 67 patients (84%) had sustained success since 12 months, of whom 45 of 67 (67%) were dry (Stamey grade 0). Of the dry patients at 12 months 33 of 38 (87%) maintained cure at 24 months. Also, 12 of 29 patients (41%) considered improved at 12 months were dry at 24 months. Overall Incontinence Quality of Life scores and all subscales showed statistically significant improvement from baseline (p <0.001). Mean pad weight was 24 gm at baseline, and 4 gm at 12 and 24 months. Patient and physician assessments rated 85% of patients dry or markedly improved 24 months after the last treatment. Conclusions: Substantial, durable results were sustained during 2 years with 84% of patients maintaining significant Stamey grade improvement from the 12-month assessment. Two-thirds of patients were dry at 24 months. The durability of Macroplastique shows its effectiveness as a viable long-term therapy for female stress urinary incontinence primarily due to intrinsic sphincter deficiency.

Original languageEnglish (US)
Pages (from-to)1444-1449
Number of pages6
JournalJournal of Urology
Volume183
Issue number4
DOIs
StatePublished - Apr 1 2010

Fingerprint

Stress Urinary Incontinence
Multicenter Studies
Injections
Incontinence Pads
Quality of Life
Physicians
Weights and Measures
Therapeutics
Outcome Assessment (Health Care)
Safety

Keywords

  • injections
  • silicone elastomers
  • stress
  • urethra
  • urinary incontinence

ASJC Scopus subject areas

  • Urology

Cite this

Durability of Urethral Bulking Agent Injection for Female Stress Urinary Incontinence : 2-Year Multicenter Study Results. / Ghoniem, Gamal; Corcos, Jacques; Comiter, Craig; Westney, O. Lenaine; Herschorn, Sender.

In: Journal of Urology, Vol. 183, No. 4, 01.04.2010, p. 1444-1449.

Research output: Contribution to journalArticle

Ghoniem, Gamal ; Corcos, Jacques ; Comiter, Craig ; Westney, O. Lenaine ; Herschorn, Sender. / Durability of Urethral Bulking Agent Injection for Female Stress Urinary Incontinence : 2-Year Multicenter Study Results. In: Journal of Urology. 2010 ; Vol. 183, No. 4. pp. 1444-1449.
@article{0be22bff0b7a4235acb41e7deac0f739,
title = "Durability of Urethral Bulking Agent Injection for Female Stress Urinary Incontinence: 2-Year Multicenter Study Results",
abstract = "Purpose: We evaluated the durability of the urethral bulking agent Macroplastique{\circledR} for stress urinary incontinence in a 24-month study in women with a previously documented successful outcome 12 months after the last injection. Materials and Methods: In a multicenter study females diagnosed with stress urinary incontinence primarily due to intrinsic sphincter deficiency successfully treated with Macroplastique, defined as 1 or greater Stamey grade improvement 12 months from baseline, were followed for 24 months to assess the sustained therapeutic response. Outcome measures were Stamey grade, Patient Global Impression of Improvement, Physician Assessment of Improvement, 1-hour pad weight, Incontinence Quality of Life scores and safety assessment. Results: At 24 months 56 of 67 patients (84{\%}) had sustained success since 12 months, of whom 45 of 67 (67{\%}) were dry (Stamey grade 0). Of the dry patients at 12 months 33 of 38 (87{\%}) maintained cure at 24 months. Also, 12 of 29 patients (41{\%}) considered improved at 12 months were dry at 24 months. Overall Incontinence Quality of Life scores and all subscales showed statistically significant improvement from baseline (p <0.001). Mean pad weight was 24 gm at baseline, and 4 gm at 12 and 24 months. Patient and physician assessments rated 85{\%} of patients dry or markedly improved 24 months after the last treatment. Conclusions: Substantial, durable results were sustained during 2 years with 84{\%} of patients maintaining significant Stamey grade improvement from the 12-month assessment. Two-thirds of patients were dry at 24 months. The durability of Macroplastique shows its effectiveness as a viable long-term therapy for female stress urinary incontinence primarily due to intrinsic sphincter deficiency.",
keywords = "injections, silicone elastomers, stress, urethra, urinary incontinence",
author = "Gamal Ghoniem and Jacques Corcos and Craig Comiter and Westney, {O. Lenaine} and Sender Herschorn",
year = "2010",
month = "4",
day = "1",
doi = "10.1016/j.juro.2009.12.038",
language = "English (US)",
volume = "183",
pages = "1444--1449",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Durability of Urethral Bulking Agent Injection for Female Stress Urinary Incontinence

T2 - 2-Year Multicenter Study Results

AU - Ghoniem, Gamal

AU - Corcos, Jacques

AU - Comiter, Craig

AU - Westney, O. Lenaine

AU - Herschorn, Sender

PY - 2010/4/1

Y1 - 2010/4/1

N2 - Purpose: We evaluated the durability of the urethral bulking agent Macroplastique® for stress urinary incontinence in a 24-month study in women with a previously documented successful outcome 12 months after the last injection. Materials and Methods: In a multicenter study females diagnosed with stress urinary incontinence primarily due to intrinsic sphincter deficiency successfully treated with Macroplastique, defined as 1 or greater Stamey grade improvement 12 months from baseline, were followed for 24 months to assess the sustained therapeutic response. Outcome measures were Stamey grade, Patient Global Impression of Improvement, Physician Assessment of Improvement, 1-hour pad weight, Incontinence Quality of Life scores and safety assessment. Results: At 24 months 56 of 67 patients (84%) had sustained success since 12 months, of whom 45 of 67 (67%) were dry (Stamey grade 0). Of the dry patients at 12 months 33 of 38 (87%) maintained cure at 24 months. Also, 12 of 29 patients (41%) considered improved at 12 months were dry at 24 months. Overall Incontinence Quality of Life scores and all subscales showed statistically significant improvement from baseline (p <0.001). Mean pad weight was 24 gm at baseline, and 4 gm at 12 and 24 months. Patient and physician assessments rated 85% of patients dry or markedly improved 24 months after the last treatment. Conclusions: Substantial, durable results were sustained during 2 years with 84% of patients maintaining significant Stamey grade improvement from the 12-month assessment. Two-thirds of patients were dry at 24 months. The durability of Macroplastique shows its effectiveness as a viable long-term therapy for female stress urinary incontinence primarily due to intrinsic sphincter deficiency.

AB - Purpose: We evaluated the durability of the urethral bulking agent Macroplastique® for stress urinary incontinence in a 24-month study in women with a previously documented successful outcome 12 months after the last injection. Materials and Methods: In a multicenter study females diagnosed with stress urinary incontinence primarily due to intrinsic sphincter deficiency successfully treated with Macroplastique, defined as 1 or greater Stamey grade improvement 12 months from baseline, were followed for 24 months to assess the sustained therapeutic response. Outcome measures were Stamey grade, Patient Global Impression of Improvement, Physician Assessment of Improvement, 1-hour pad weight, Incontinence Quality of Life scores and safety assessment. Results: At 24 months 56 of 67 patients (84%) had sustained success since 12 months, of whom 45 of 67 (67%) were dry (Stamey grade 0). Of the dry patients at 12 months 33 of 38 (87%) maintained cure at 24 months. Also, 12 of 29 patients (41%) considered improved at 12 months were dry at 24 months. Overall Incontinence Quality of Life scores and all subscales showed statistically significant improvement from baseline (p <0.001). Mean pad weight was 24 gm at baseline, and 4 gm at 12 and 24 months. Patient and physician assessments rated 85% of patients dry or markedly improved 24 months after the last treatment. Conclusions: Substantial, durable results were sustained during 2 years with 84% of patients maintaining significant Stamey grade improvement from the 12-month assessment. Two-thirds of patients were dry at 24 months. The durability of Macroplastique shows its effectiveness as a viable long-term therapy for female stress urinary incontinence primarily due to intrinsic sphincter deficiency.

KW - injections

KW - silicone elastomers

KW - stress

KW - urethra

KW - urinary incontinence

UR - http://www.scopus.com/inward/record.url?scp=77949288876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949288876&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2009.12.038

DO - 10.1016/j.juro.2009.12.038

M3 - Article

C2 - 20171691

AN - SCOPUS:77949288876

VL - 183

SP - 1444

EP - 1449

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 4

ER -